How Pfizer Stock Can Rebound
Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer.
What Analyst Projections for Key Metrics Reveal About Pfizer (PFE) Q3 Earnings
Evaluate the expected performance of Pfizer (PFE) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker.
Denmark's Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.
Novo Nordisk Moves to Outbid Pfizer With Up to $9 Billion Offer for Obesity Drug Developer Metsera
Novo Nordisk said the proposal is currently subject to review by Metsera's board of directors.
Novo Nordisk gatecrashes Pfizer's takeover of obesity rival Metsera
Novo Nordisk (NYSE:NVO) has attempted to gatecrash Pfizer Inc (NYSE:PFE, ETR:PFE)deal to buy obesity drug developer Metsera Inc (NASDAQ:MTSR), with an unsolicited offer of $6.5 billion, rising to a potential $9 billion. The Danish drugmaker became Europe's largest company after being first to market with anti-obesity drugs but has lost its lead and its crown after being usurped by rival products.
Novo Nordisk said to make higher bid for Metsera to challenge Pfizer, Bloomberg News reports
Danish drugmaker Novo Nordisk has made a higher offer for Metsera seeking to trump an agreed deal with Pfizer so it can consolidate its position in weight-loss medications, Bloomberg News reported on Thursday citing people with knowledge of the matter.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
Pfizer (PFE) closed at $24.5 in the latest trading session, marking a -1.09% move from the prior day.
Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Pfizer's Headwinds May Already Be In The Price
Pfizer faces significant revenue headwinds from patent expiries, COVID product declines, and generic competition, but these risks are largely priced in. PFE's valuation is historically low at ~8x earnings, reflecting aggressive patent cliff assumptions and conservative growth projections for existing products. Pipeline and acquisition success, especially in obesity/diabetes, could drive capital appreciation, with even partial wins supporting a rerating toward historical multiples.
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space.
2 Safer High-Yield Stocks That Can Pay Boomers for Life
Baby Boomers should be looking to play things a bit more cautiously as stock valuations begin to climb across the board.
Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients
Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, progression or death in patients suffering from a type of bladder cancer, the companies said on Saturday.
